Differences in UK healthcare professionals’ knowledge, attitude and practice towards infliximab and insulin glargine biosimilars-Reference-Cited by-同舟云学术

Differences in UK healthcare professionals’ knowledge, attitude and practice towards infliximab and insulin glargine biosimilars

Published:2018-08-30 Issue:2 Volume:27 Page:214-217
ISSN:0961-7671
Container-title:International Journal of Pharmacy Practice
language:en
Short-container-title:

Author:

Aladul Mohammed I¹²^ORCID,Fitzpatrick Raymond W¹,Chapman Stephen R¹^ORCID

Affiliation:

1. School of Pharmacy, Keele University, Keele, UK

2. School of Pharmacy, University of Mosul, Mosul, Nineveh, Iraq

Abstract

Abstract Objectives To investigate knowledge and attitudes of different healthcare professionals in UK towards infliximab and insulin glargine biosimilars Methods UK medical consultants/registrars, nurses and pharmacists participated in anonymised, self-administered web-based survey distributed by professional associations. Key findings There were 234 respondents: medical consultants/registrars (150), nurses (58) and pharmacists (26). 76% of medical consultants/registrars, 84% of pharmacists and 53% of nurses understood what biosimilars were. Medical consultants/registrars and pharmacists had safety and efficacy concerns when switching patients compared to initiation. Nurses had similar levels of safety and efficacy concerns about initiation. Conclusion Healthcare professionals were more comfortable with the initiation of biosimilars than switching current patients. Medical consultants/registrars and pharmacists were more informed than nurses.

Publisher

Oxford University Press (OUP)

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmaceutical Science,Pharmacy

Link

http://academic.oup.com/ijpp/article-pdf/27/2/214/36596400/ijpp12485.pdf

Reference10 articles.

1. The emergence of biosimilar insulin preparations—a cause for concern?;Owens;Diabetes Technol Ther,2012

2. Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists;Grabowski;Clin Rheumatol,2015

3. Awareness, knowledge, and perceptions of biosimilars among specialty physicians;Cohen;Adv Ther,2017

4. Biosimilar medicines and their use: the nurses’ responsibility;Salem;Ren Soc Aust J,2010

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How Does an Integrated Pharmacist Add Value in the Management of Inflammatory Bowel Disease in the Era of Values-Based Healthcare?;Inflammatory Bowel Diseases;2024-08-29

2. Barriers and Enablers Affecting the Uptake of Biosimilar Medicines Viewed Through the Lens of Actor Network Theory: A Systematic Review;BioDrugs;2024-06-15

3. Unveiling the Biosimilar Paradox of Oncologists’ Perceptions and Hesitations in South Korea: A Web-Based Survey Study;BioDrugs;2024-01-12

4. Biosimilars;Journal of Infusion Nursing;2024-01

5. Perception of pharmacological equivalence of generics or biosimilars in healthcare professionals in Vienna;European Journal of Clinical Pharmacology;2023-12-22